{
    "id": 25816,
    "fullName": "MST1R dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MST1R (RON) dec exp indicates decreased expression of the Mst1r (Ron) protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4486,
        "geneSymbol": "MST1R",
        "terms": [
            "MST1R",
            "CD136",
            "CDw136",
            "NPCA3",
            "PTK8",
            "RON",
            "SEA"
        ]
    },
    "variant": "dec exp",
    "createDate": "12/16/2016",
    "updateDate": "02/11/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9606,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of MST1R (RON) increased sensitivity of a bladder carcinoma cell line to Adriamycin (doxirubicin) under hypoxia in culture, resulting in decreased cell survival (PMID: 26772202).",
            "molecularProfile": {
                "id": 26918,
                "profileName": "MST1R dec exp"
            },
            "therapy": {
                "id": 1009,
                "therapyName": "Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7317,
                    "pubMedId": 26772202,
                    "title": "RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Break-Inducing Anticancer Drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26772202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9607,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of MST1R (RON) increased sensitivity of a bladder carcinoma cell line to Ellence (epirubicin) under hypoxia in culture, resulting in decreased cell survival (PMID: 26772202).",
            "molecularProfile": {
                "id": 26918,
                "profileName": "MST1R dec exp"
            },
            "therapy": {
                "id": 1013,
                "therapyName": "Epirubicin",
                "synonyms": null
            },
            "indication": {
                "id": 4007,
                "name": "bladder carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7317,
                    "pubMedId": 26772202,
                    "title": "RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Break-Inducing Anticancer Drugs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26772202"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26918,
            "profileName": "MST1R dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}